Best of ASCO® Toronto 2024: Gynecological Cancer – Dr. Stéphanie Lheureux
OR
Co-Chairs
Dr. Aly-Khan Lalani
Dr. Natasha Leighl
Speakers
Dr. Stéphanie Lheureux
Studies/trials discussed:
- Adjuvant chemotherapy following concurrent chemoradiation (CRT) in patients with high-risk early-stage cervical carcinoma following radical hysterectomy
- Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial
- Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in
- platinum-sensitive relapsed ovarian cancer (SOC-1): A final overall survival analysis
- of a multicenter, open-label, randomized, phase 3 trial.
- Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20.
- A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (NEO)
- Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A).
- Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in
- combination with ipilimumab for people with ovarian and other extra-renal clear cell
- carcinomas.
